1887

Abstract

Daptomycin is licensed for the management of infections in adults, including those caused by meticillin-resistant (MRSA). Few data exist on paediatric use or dose guidance in neonates. We report the case of a neonate with MRSA bacteraemia successfully managed with daptomycin. Dose requirements were substantially higher than those recommended for adults.

Keyword(s): i.v., intravenous
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.027235-0
2011-03-01
2020-05-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/3/381.html?itemId=/content/journal/jmm/10.1099/jmm.0.027235-0&mimeType=html&fmt=ahah

References

  1. Abdel-Rahman S. M., Benziger D. P., Jacobs R. F., Jafri H. S., Hong E. F., Kearns G. L. 2008; Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 27:330–334 [CrossRef]
    [Google Scholar]
  2. Carey A. J., Long S. S. 2010; Staphylococcus aureus : a continuously evolving and formidable pathogen in the neonatal intensive care unit. Clin Perinatol 37:535–546 [CrossRef]
    [Google Scholar]
  3. Cohen-Wolkowiez M., Smith P. B., Benjamin D. K. Jr, Fowler V. G. Jr, Wade K. C. 2008; Daptomycin use in infants: report of two cases with peak and trough drug concentrations. J Perinatol 28:233–234 [CrossRef]
    [Google Scholar]
  4. Dvorchik B. H., Brazier D., DeBruin M. F., Arbeit R. D. 2003; Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 47:1318–1323 [CrossRef]
    [Google Scholar]
  5. Hawkey P. M. 2008; Pre-clinical experience with daptomycin. J Antimicrob Chemother 62 (Suppl. 3):iii7–iii14
    [Google Scholar]
  6. Johnson A. P., Sharland M., Goodall C. M., Blackburn R., Kearns A. M., Gilbert R., Lamagni T. L., Charlett A., Ganner M. other authors 2010; Enhanced surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in children in the UK and Ireland. Arch Dis Child 95:781–785 [CrossRef]
    [Google Scholar]
  7. Kanafani Z. A., Corey G. R. 2007; Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther 5:177–184 [CrossRef]
    [Google Scholar]
  8. Lodise T. P., Graves J., Evans A., Graffunder E., Helmecke M., Lomaestro B. M., Stellrecht K. 2008; Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52:3315–3320 [CrossRef]
    [Google Scholar]
  9. Moise P. A., Sakoulas G., Forrest A., Schentag J. J. 2007; Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteraemia. Antimicrob Agents Chemother 51:2582–2586 [CrossRef]
    [Google Scholar]
  10. Tobin C. M., Darville J. M., Lovering A. M., Macgowan A. P. 2008; An HPLC assay for daptomycin in serum. J Antimicrob Chemother 62:1462–1463 [CrossRef]
    [Google Scholar]
  11. Yoon Y. K., Kim J. Y., Park D. W., Sohn J. W., Kim M. J. 2010; Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrob Chemother 65:1015–1018 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.027235-0
Loading
/content/journal/jmm/10.1099/jmm.0.027235-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error